Theranostics News and Research

RSS

New PET imaging approach may enable early CTE diagnosis

A first-in-class PET imaging approach can accurately detect a biomarker for chronic traumatic encephalopathy (CTE), a devastating neurodegenerative disease associated with repeated head impact.

31 May 2026

Predictive model helps tailor PSMA therapy for prostate cancer patients

A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy begins.

31 May 2026

New drug carrier improves cancer treatment by anchoring to tumors

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target. But drugs also need time to work, which means they need to stay near the diseased tissues long enough.

13 May 2026

Pretargeted radioimmunotherapy shows promise for colorectal cancer treatment

A new pretargeted radioimmunotherapy (PRIT) technique has been shown to be safe and effective in eradicating tumors from a preclinical colorectal cancer model.

30 Apr 2026

Virginia Tech team identifies proteins that can reverse lung scarring

A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in pre-clinical models.

28 Apr 2026

PSMA PET/CT scan may halve unnecessary prostate biopsies

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found.

12 Mar 2026

Targeted PET/CT tracer improves early prediction of treatment response in rheumatoid arthritis patients

A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little as four weeks, and potentially even at the start of treatment, according to new research published in The Journal of Nuclear Medicine.

27 Feb 2026

Imaging technique can objectively identify a recently recognized type of dementia, LATE

A novel quantitative PET- and MRI-based imaging approach can objectively identify a recently recognized type of dementia--limbic-predominant age-related TDP-43 encephalopathy, or LATE--that is often mistaken as Alzheimer's disease.

26 Feb 2026

Researchers discover a way to breach cancer’s impenetrable fortress

Researchers at Case Western Reserve University have discovered a way to breach one of cancer's most stubborn defenses: the impenetrable fortress that solid tumors build around themselves.

18 Feb 2026

Siemens Healthineers and Mayo Clinic expand partnership to fight neurodegenerative disease, cancer

Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors.

13 Feb 2026

Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

16 Jan 2026

Global nuclear medicine organizations unite to standardize quantitative PET imaging

Three world-leading nuclear medicine organizations--the SNMMI Clinical Trials Network (SNMMI-CTN), the Australasian Radiopharmaceutical Trials Network (ARTnet), and the European Association of Nuclear Medicine Forschungs GmbH (EARL)--have jointly endorsed a unified PET/CT and PET/MR scanner accreditation framework to standardize and harmonize quantitative PET imaging worldwide.

16 Dec 2025

Targeted mRNA vaccines train the immune system to destroy cancer cells

No matter where cancer cells grow in the human body, they are a threat to our health and our lives. But instead of treating them with chemotherapy or radiation - which have undesirable side effects - what if we could train our own immune systems to kill the rogue cells?

16 Dec 2025

$New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer$

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs.

5 Dec 2025

Shorter hormone therapy may be enough for many men with prostate cancer

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first 9 to 12 months.

25 Nov 2025

New radioimmunotherapy approach shows potential to cure HER2-positive breast cancer

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine.

7 Nov 2025

Novel PET scan quickly predicts functional recovery after heart attack

A new approach to PET imaging offers a promising way for physicians to promptly identify patients who are at risk for poor functional recovery after a heart attack, according to new research published in The Journal of Nuclear Medicine.

23 Oct 2025

Researchers develop a novel approach to monitor CD8⁺ T cell activity over time

The ability of immune cells-particularly CD8+ T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies.

21 Oct 2025

Novel combination therapy shows promise for advanced neuroendocrine tumors

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented this week at the European Society for Medical Oncology (ESMO) Congress 2025.

21 Oct 2025

UCLA presents advances in radiation therapy at ASTRO 2025

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on targeted radioactive therapy for recurrent prostate cancer, new approaches to stereotactic body radiation for prostate and head and neck cancers, advances in MRI- and 5DCT-guided imaging for more precise treatments, and innovations in patient-focused cancer education.

26 Sep 2025